OR WAIT null SECS
December 12, 2016
Alvogen (Pine Brook, NJ) has launched the first generic equivalent to Roche's Tamiflu (oseltamivir phosphate) capsules in the United States. Alvogen reports that it expects the capsules "to deliver significant savings for patients and health providers of up to $500 million during this upcoming season." The product is available in three strengths (30 mg, 45 mg and 75 mg). A consortium of investors, led by CVC Capital Partners and including Singapore-based investment company Temasek and Vatera Healthcare Partners, acquired a majority stake in Alvogen in June 2015.